C
Cyril H. Benes
Researcher at Harvard University
Publications - 188
Citations - 23280
Cyril H. Benes is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Targeted therapy. The author has an hindex of 61, co-authored 176 publications receiving 18052 citations. Previous affiliations of Cyril H. Benes include Helmholtz-Zentrum Dresden-Rossendorf & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang,Jorge Soares,Patricia Greninger,Elena J. Edelman,Howard Lightfoot,Simon A. Forbes,Nidhi Bindal,Dave Beare,James Smith,I. Richard Thompson,Sridhar Ramaswamy,P. Andrew Futreal,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Ultan McDermott,Mathew J. Garnett +16 more
TL;DR: The Genomics of Drug Sensitivity in Cancer (GDSC) provides a unique resource incorporating large drug sensitivity and genomic datasets to facilitate the discovery of new therapeutic biomarkers for cancer therapies.
Journal ArticleDOI
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio,Francesco Iorio,Theo A. Knijnenburg,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Michael P. Menden,Michael Schubert,Nanne Aben,Nanne Aben,Emanuel Gonçalves,Syd Barthorpe,Howard Lightfoot,Thomas Cokelaer,Thomas Cokelaer,Patricia Greninger,Ewald van Dyk,Han Chang,Heshani de Silva,Holger Heyn,Xianming Deng,Regina K. Egan,Qingsong Liu,Tatiana Mironenko,Xeni Mitropoulos,Laura Richardson,Jinhua Wang,Tinghu Zhang,Sebastian Moran,Sergi Sayols,Maryam Soleimani,David Tamborero,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Petra Ross-Macdonald,Manel Esteller,Manel Esteller,Nathanael S. Gray,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +48 more
TL;DR: It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.
Journal ArticleDOI
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama,Alice T. Shaw,Alice T. Shaw,Tahsin M. Khan,Tahsin M. Khan,Mari Mino-Kenudson,Benjamin Solomon,Balazs Halmos,Nicholas A. Jessop,John C. Wain,Alan Tien Yeo,Cyril H. Benes,Lisa Drew,Jamal Carlos Saeh,Katherine Crosby,Lecia V. Sequist,A. John Iafrate,Jeffrey A. Engelman +17 more
TL;DR: Findings from a series of lung cancer patients with acquired resistance to the ALK TKI crizotinib reinforce the need to tailor therapeutic strategies to the specific underlying drug resistance mechanisms in the tumors to improve clinical outcomes.
Journal ArticleDOI
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor,Leila Dardaei,Satoshi Yoda,Luc Friboulet,Ignaty Leshchiner,Ryohei Katayama,Ibiayi Dagogo-Jack,Shirish M. Gadgeel,Katherine Schultz,Manrose Singh,Emily Chin,Melissa Parks,Dana Lee,Richard H. DiCecca,Elizabeth L. Lockerman,Tiffany Huynh,Jennifer A. Logan,Lauren L. Ritterhouse,Long P. Le,Ashok Muniappan,Subba R. Digumarthy,Colleen L. Channick,Colleen Keyes,Gad Getz,Dora Dias-Santagata,Rebecca S. Heist,Jochen K. Lennerz,Lecia V. Sequist,Cyril H. Benes,A. John Iafrate,Mari Mino-Kenudson,Jeffrey A. Engelman,Alice T. Shaw +32 more
TL;DR: Analysis of repeat biopsies from ALK-positive patients progressing on various ALK inhibitors finds that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation - ALK G1202R - increases significantly after treatment with second-generation agents.